# Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

> **NCT05394103** · PHASE1,PHASE2 · RECRUITING · sponsor: **Qurient Co., Ltd.** · enrollment: 130 (estimated)

## Conditions studied

- Advanced Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** Q901
- **DRUG:** KEYTRUDA® (pembrolizumab)

## Key facts

- **NCT ID:** NCT05394103
- **Lead sponsor:** Qurient Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-30
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-08-30
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2025-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05394103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05394103, "Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05394103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*